altretamine has been researched along with razoxane in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (88.89) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Carter, SK; Slavik, M | 1 |
| Brunner, KW; Cavalli, F | 1 |
| Cavalli, F | 1 |
| Carter, WH; Crews, SL; Howells, R; Wampler, GL | 1 |
| Carchman, RA; Carter, WH | 1 |
| Davey, P; Tudhope, GR | 1 |
| Carter, WH; Stablein, DM; Wampler, GL | 1 |
2 review(s) available for altretamine and razoxane
| Article | Year |
|---|---|
Current investigational drugs of interest in the Chemotherapy Program of the National Cancer Institute.
Topics: Altretamine; Animals; Antineoplastic Agents; Asparaginase; Azacitidine; Bleomycin; Cisplatin; Dacarbazine; Doxorubicin; Drug Evaluation; Female; Guanazole; Humans; Ifosfamide; Male; National Institutes of Health (U.S.); Neoplasms; Nitrogen Mustard Compounds; Nitrosourea Compounds; Razoxane; United States | 1977 |
[New substances in oncologic therapy].
Topics: Alkylating Agents; Altretamine; Antimetabolites, Antineoplastic; Cisplatin; Dacarbazine; Doxorubicin; Drug Evaluation; Drug Evaluation, Preclinical; Etoposide; Humans; Neoplasms; Nitrosourea Compounds; Razoxane; Tamoxifen; Vinca Alkaloids; Zinostatin | 1978 |
1 trial(s) available for altretamine and razoxane
| Article | Year |
|---|---|
[New substances in oncologic therapy].
Topics: Altretamine; Ancitabine; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Cisplatin; Clinical Trials as Topic; Dacarbazine; Doxorubicin; Drug Evaluation; Drug Therapy, Combination; Etoposide; Humans; Mitolactol; Nitrosourea Compounds; Razoxane; Remission, Spontaneous; Tamoxifen; Time Factors; Vinca Alkaloids; Zinostatin | 1978 |
6 other study(ies) available for altretamine and razoxane
| Article | Year |
|---|---|
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
On determining the levels of treatment to optimize the probability of a favorable response.
Topics: Altretamine; Animals; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Leukemia L1210; Mice; Mice, Inbred Strains; Models, Biological; Neoplasms; Razoxane; Statistics as Topic | 1977 |
Mathematical and biostatistical methods for designing and analyzing complex chemical interactions.
Topics: Altretamine; Animals; Cisplatin; Drug-Related Side Effects and Adverse Reactions; Fluorouracil; Mice; Mice, Inbred Strains; Models, Chemical; Razoxane; Sister Chromatid Exchange; Statistics as Topic | 1988 |
Phase II trials of hexamethylmelamine, dianhydrogalactitol, razoxane, and beta-2'-deoxythioguanosine as single agents against advanced measurable tumors of the pancreas. Gastrointestinal Tumor Study Group.
Topics: Adenocarcinoma; Altretamine; Antineoplastic Agents; Deoxyguanosine; Dianhydrogalactitol; Drug Evaluation; Humans; Leukopenia; Pancreatic Neoplasms; Piperazines; Razoxane; Sugar Alcohols; Thionucleosides; Thrombocytopenia; Triazines | 1985 |
Anticancer chemotherapy.
Topics: Alkylating Agents; Altretamine; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Cisplatin; Etoposide; Humans; Mitobronitol; Mitolactol; Nitrosourea Compounds; Razoxane; Vinca Alkaloids | 1983 |
Survival analysis of drug combinations using a hazards model with time-dependent covariates.
Topics: Altretamine; Animals; Antineoplastic Agents; Disease Models, Animal; Drug Therapy, Combination; Female; Leukemia L1210; Mice; Razoxane; Risk | 1980 |